Luitpold Pharmaceuticals, Inc. Invests in BioMimetic Therapeutics, Inc.

We advised BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) in the sale of its orofacial therapeutic business, including its bone and tissue regeneration treatment, GEM 21S and related intellectual property, to Luitpold Pharmaceuticals, Inc., a division of Daiichi Sankyo Co. Ltd of Japan. Under the agreement Luitpold has agreed to pay BioMimetic approximately $45 million in cash, in addition to royalty payments based on sales of existing and future products in the dental and orofacial therapeutic fields. 

The sale allows BioMimetic to refocus its business on the development and commercialization of its orthopedic and sports medicine products, GEM OS1 and GEM OS2.

This experience gained prior to joining Bass, Berry & Sims PLC.

You Also May Be Interested In:

  • Successfully represented AmSurg Holdings, Inc. in a dispute with a group of physicians seeking to invalidate a non-compete provision that was a material feature of a highly profitable surgery center partnership located in  Minnesota

    We represented AmSurg Holdings, Inc. in a dispute with a group of physicians seeking to invalidate a non-compete provision that...
    Client Type: Public Company
  • Representation of Triage Consulting Group, a healthcare revenue integrity company in its acquisition by Revint Solutions, a leader in technology-enabled revenue integrity solutions for healthcare providers

    We represented Triage Consulting Group, a healthcare revenue integrity company in its acquisition by Revint Solutions, a leader in technology-enabled...
    Client Type: Private Company
  • A team of pro bono lawyers in our Memphis office represented Neighborhood Preservation Inc. (NPI) in acquiring a number of...
    Client Type: Pro Bono